Repro Med Ownership
| KRMD Stock | USD 2.95 0.03 1.03% |
Shares in Circulation | First Issued 2000-03-31 | Previous Quarter 45.9 M | Current Value 45.8 M | Avarage Shares Outstanding 34.9 M | Quarterly Volatility 7.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Repro |
Repro Stock Ownership Analysis
About 51.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.13. Repro Med Systems had not issued any dividends in recent years. KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. Koru Medical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Repro Med Systems contact Linda Tharby at 800 624 9600 or learn more at https://www.korumedical.com.Besides selling stocks to institutional investors, Repro Med also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Repro Med's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Repro Med's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Repro Med Quarterly Liabilities And Stockholders Equity |
|
Repro Med Insider Trades History
About 7.0% of Repro Med Systems are currently held by insiders. Unlike Repro Med's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Repro Med's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Repro Med's insider trades
Repro Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Repro Med is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Repro Med Systems backward and forwards among themselves. Repro Med's institutional investor refers to the entity that pools money to purchase Repro Med's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | White Pine Capital Llc | 2024-12-31 | 157.9 K | State Street Corp | 2024-12-31 | 135.6 K | Washington Trust Co | 2024-12-31 | 100 K | Pnc Financial Services Group Inc | 2024-12-31 | 97 K | Empire Financial Management Company, Llc | 2024-12-31 | 95 K | 683 Capital Management Llc | 2024-12-31 | 88.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 86.3 K | Goldman Sachs Group Inc | 2024-12-31 | 83.9 K | Northern Trust Corp | 2024-12-31 | 79.2 K | First Light Asset Management, Llc | 2024-12-31 | 5.9 M | Topline Capital Management Llc | 2024-12-31 | 4.3 M |
Repro Med Systems Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repro Med insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repro Med's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Repro Med insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Repro Med Outstanding Bonds
Repro Med issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Repro Med Systems uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Repro bonds can be classified according to their maturity, which is the date when Repro Med Systems has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Repro Med Corporate Filings
8K | 12th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 7th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of January 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.13) | Revenue Per Share | Quarterly Revenue Growth 0.23 | Return On Assets |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.